不同类型疫苗间抗RBD SARS-CoV-2 IgG抗体反应的有效性和持续时间比较:对疫苗策略的启示
该研究于2021年2月至9月采集约旦King Hussein癌症中心2065名血库献血者和医护人员的样本,用化学发光微粒子免疫分析法检测抗Spike/RBD IgG水平,比较Pfizer/BioNTech、AstraZeneca、Sputnik V、Johnson & Johnson、Moderna和Sinopharm等新冠疫苗诱导的抗RBD IgG抗体平均滴度、持续时间及突破性感染易感性。结果显示不同疫苗类型间平均滴度显著不同,接种第三剂加强针者滴度最高,Pfizer组接种后平均滴度最高但60天后开始下降,而AstraZeneca和Sinopharm组滴度持续稳定至120天但水平显著较低;突破性感染多发生于Sinopharm接种组。
要点
- 接种第三剂加强针者抗RBD IgG平均滴度最高。
- Pfizer组接种后平均滴度最高,但60天后开始下降。
- AstraZeneca和Sinopharm组滴度稳定至120天但水平显著较低。
核心结论
- 抗RBD IgG平均滴度在四个月后下降,此时是接种更有效疫苗类型(如mRNA疫苗)加强针的最佳时机,约旦和全球可能需要。
研究设计与样本
- 研究于2021年2月至9月采集约旦King Hussein癌症中心2065名血库献血者和医护人员的样本。
- 使用化学发光微粒子免疫分析法(CMIA)(ARCHITECT IgG II Quant test, Abbott, USA)检测抗Spike/RBD IgG水平。
- 比较Pfizer/BioNTech、AstraZeneca、Sputnik V、Johnson & Johnson、Moderna和Sinopharm新冠疫苗受种者的抗RBD IgG平均滴度、持续时间及突破性感染易感性。
主要发现
- 不同疫苗类型间抗RBD IgG平均滴度显著不同。
- 接种第三剂加强针者平均滴度最高,其后依次为Pfizer/BioNTech、AstraZeneca和Sinopharm疫苗。
- Pfizer接种组接种后平均滴度最高,但接种60天后开始下降,而AstraZeneca和Sinopharm疫苗诱导的抗体平均滴度持续稳定至120天但水平显著较低。
- 突破性感染多发生于Sinopharm接种组,且三种主要疫苗类型的突破性感染发生时间随机。
临床怎么用
- 作者认为四个月后是接种更有效疫苗类型(如mRNA疫苗)加强针的最佳时机,约旦和全球可能需要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Little is known about the efficacy and durability of anti-RBD IgG antibodies induced by certain SARS-CoV-2 vaccines. It has been shown that neutralizing antibodies are associated with the protection against re-infection. This study aims to compare the mean titers, duration, and efficacy of generating protective anti-RBD IgG antibody response among recipients of Pfizer/BioNTech, AstraZeneca, Sputnik V, Johnson & Johnson, Moderna, and Sinopharm COVID-19 vaccines. In addition, we aimed to compare the susceptibility of getting COVID-19 breakthrough infections after various types of vaccines. MATERIALS AND METHODS: Samples from 2065 blood bank donors and healthcare workers at King Hussein Cancer Center (KHCC) were collected between February and September 2021. Anti-Spike/RBD IgG levels were measured using Chemiluminescent microparticle-immunoassay (CMIA) (ARCHITECT IgG II Quant test, Abbott, USA). RESULTS: The mean titer of anti-RBD IgG levels was significantly diverse among different types of vaccines. The highest titer level was seen in participants who took a third booster vaccine shot, followed by Pfizer/BioNTech, AstraZeneca, and Sinopharm vaccine. The mean titer levels of anti-RBD IgG antibodies in the Pfizer vaccinated group was the highest after vaccination but started to drop after 60 days from vaccination unlike AstraZeneca and Sinopharm vaccine-induced antibodies where the mean titers continued to be stable until 120 days but their levels were significantly lower. Most of the breakthrough infections were among the Sinopharm vaccinated group and these breakthroughs happened at random times for the three main types of vaccines. CONCLUSIONS: Our data demonstrate that the mean-titer of anti-RBD IgG levels drop after four months which is the best time to take the additional booster shot from a more potent vaccine type such as mRNA vaccines that might be needed in Jordan and worldwide.
引用
- Sughayer MA, Souan L, Abu Alhowr MM, et al. Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies. Vaccine. 2022. PMID: 35397946. doi:10.1016/j.vaccine.2022.03.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。